Background Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of ...
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
Onlymyhealth on MSN
Beyond the Cough: Expert Shares 7 Subtle Signs of Lung Disease
When everybody thinks about lung disease, a long cough is the initial symptom that comes to mind. However, respiratory ...
Japanese and US researchers have developed a groundbreaking treatment for people who can’t breathe through their lungs — by ...
It’s still early days. Nobody’s suggesting we’ll all start “breathing through our butts.” But medical innovation has a habit ...
Adding cardiopulmonary exercise testing parameters does not significantly improve machine learning-based prediction of ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares sank 50% on Wednesday after the company reported interim Phase 2 ...
The San Diego-based mRNA medicines company reported that its investigational inhaled therapy ARCT-032 was generally safe and well-tolerated in the second cohort of its ongoing Phase 2 trial. Six ...
Nevada veterans are awaiting the final passage of S.2220, a landmark bill that would acknowledge those who served at the radioactive Nevada Test and Training Range.
Yutrepia was well tolerated and improved 6-minute walk distance and cardiac effort at 16 weeks in patients with pulmonary ...
Ensifentrine significantly improved lung function after 12 weeks in patients with moderate to severe COPD with and without ...
Most patients with persistent pulmonary symptoms after recovering from mild to moderate COVID-19 infection have normal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback